Autor(es): Cândida, Fonseca ; Rui, Baptista ; Fátima, Franco ; Brenda, Moura ; Joana, Pimenta ; Moraes Sarmento, Pedro ; José, Silva Cardoso ; Dulce, Brito
Data: 2025
Identificador Persistente: http://hdl.handle.net/10362/181549
Origem: Repositório Institucional da UNL
Assunto(s): Chronic heart failure; Emerging treatment; Expert consensus; Guideline-directed medical therapy; Management; Vericiguat; Worsening heart failure; Cardiology and Cardiovascular Medicine
Funding Information: Medical writing assistance provided by Joana Cavaco Silva, Ph.D., from ScienceCircle - Scientific and Biomedical Consulting (jo.cvsilva@gmail.com), was funded by Bayer AG. Publisher Copyright: © The Author(s) 2025.
For most patients with chronic heart failure (HF), the clinical course of the disease includes periods of apparent clinical stability punctuated by episodes of clinical deterioration with worsening signs and symptoms, a condition referred to as worsening heart failure (WHF). Over time, episodes of WHF may become more frequent, and patients may enter a cycle of recurrent events associated with deterioration in their quality of life and functional capacity, hospitalizations, and ultimately death. WHF is apparently an old concept but seems to have acquired new boundaries in terms of definition and clinical and prognostic value due to the fast-paced evolution of the HF treatment landscape and the emergence of new drugs in this setting. As a result, the management of WHF is being reshaped. In the present paper, a group of HF experts gathered to discuss the concept, prevention, detection, and treatment of WHF.
